# Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

Study · id `cardio:ct-nct05688579` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05688579](<https://clinicaltrials.gov/study/NCT05688579>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05688579

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 8000 participants.

## Technical summary

Registry record NCT05688579. Randomized; single masking; primary purpose prevention. Start 2023-04-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 8000 participants (planned count; ClinicalTrials.gov record NCT05688579, source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)
- Started: 2023-04-16 (actual) (ClinicalTrials.gov record NCT05688579, source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05688579, source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05688579, source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05688579, source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05688579-2023-04-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
- Acronym: EMRACHH
- Condition: Hypertension
- Condition: Hyperaldosteronaemia
- Intervention (Drug): Mineralocorticoid Receptor Antagonists(MRAs)
- Intervention (Other): Blank control
- Lead sponsor: Nanfang Li
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)

## Provenance

Content hash: 1b3bbd6984457a0247cbb4a4cbc53d430b29f98f28fc2b358eaeaf27c3631aef
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
